pentane has been researched along with Rhabdomyosarcoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bermúdez-Lugo, JA; Chávez-Blanco, A; Correa-Basurto, AM; Correa-Basurto, J; Dueñas-González, A; Fragoso-Vázquez, MJ; García-Sánchez, JR; Méndez-Luna, D; Mendieta-Wejebe, JE; Padilla-Martínez, II; Pérez-González, OA; Prestegui-Martel, B; Trujillo-Ferrara, J | 1 |
1 other study(ies) available for pentane and Rhabdomyosarcoma
| Article | Year |
|---|---|
N-(2-hydroxyphenyl)-2-propylpentanamide, a valproic acid aryl derivative designed in silico with improved anti-proliferative activity in HeLa, rhabdomyosarcoma and breast cancer cells.
Topics: Amides; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Computer Simulation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; HeLa Cells; Histone Deacetylases; Humans; MCF-7 Cells; Models, Molecular; Molecular Structure; Pentanes; Repressor Proteins; Rhabdomyosarcoma; Structure-Activity Relationship; Tumor Cells, Cultured; Valproic Acid | 2016 |